Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAISING 2026 INNOVATION TARGET; FULL YEAR 2026 GUIDANCE OF 4%-6% ORGANIC CONSTANT CURRENCY REVENUE GROWTH, 6%-9% ADJUSTED EBITDA GROWTH IN LINE WITH INVESTOR DAY OUTLOOK FOURTH QUARTER 2025 FINANCIAL RESULTS: REVENUE OF $1,144 MILLION, INCREASED 12% ON A REPORTED BASIS; 9% IN ORGANIC CONSTANT CURRENCY REPORTED NET LOSS OF $276 MILLION, ADJUSTED NET INCOME OF $64 MILLION ADJUSTED EBITDA OF $189 MILLION; ADJUSTED EBITDA MARGIN OF 16.7% REPORTED EPS OF $(0.56), ADJUSTED EPS OF $0.13 FULL YEAR 2025 FINANCIAL RESULTS: EXCEEDED INNOVATION REVENUE TARGET AT $892 MILLION; DELIVERED ALL 'BIG 6' BLOCKBUSTER POTENTIAL PRODUCTS BY THE END OF 2025 WITHBEFRENA APPROVAL IN Q4 2025 REVENUE OF $4,715 MILLION, INCREASED 6% ON A REPORTED BASIS AND 7% IN ORGANIC CONSTANT CURRENCY REPORTED NET LOSS OF $232 MILLION, ADJUSTED NET INCOME OF $473 MILLION ADJUSTED EBITDA OF $901 MILLION; ADJUSTED EBITDA MARGIN OF 19.2% REPORTED EPS OF $(0.47), ADJUSTED EPS OF $0.94 NET LEVERAGE RATIO OF 3.6X ADJUSTED EBITDA FULL YEAR 2026 GUIDANCE: RAISING INNOVATION REVENUE TARGET TO $1.15 BILLION REVENUE OF $4,950 MILLION TO $5,020 MILLION, OR 4% TO 6% ORGANIC CONSTANT CURRENCY GROWTH ADJUSTED EBITDA OF $955 MILLION TO $985 MILLION, AN INCREASE OF 8% AT MIDPOINT ADJUSTED EPS OF $1.00 TO $1.06, AN INCREASE OF 10% AT MIDPOINT YEAR-END NET LEVERAGE RATIO TARGET OF 3.1X TO 3.3X IN LINE WITH THREE-YEAR OUTLOOK INTRODUCED AT DECEMBER INVESTOR DAY, OUTLINING MID-SINGLE DIGIT TOP-LINE ORGANIC CONSTANT CURRENCY GROWTH, HIGH-SINGLE DIGIT ADJUSTED EBITDA GROWTH, AND LOW DOUBLE-DIGIT ADJUSTED EPS GROWTH INDIANAPOLIS, FEB. 24, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2025 AND PROVIDED INITIAL GUIDANCE FOR BOTH THE FIRST QUARTER AND FULL YEAR 2026. "ELANCO DELIVERED SIGNIFICANT PROGRESS ACROSS OUR STRATEGIC PRIORITIES OF GROWTH, INNOVATION, AND CASH IN 2025," SAID JEFF SIMMONS, PRESIDENT AND CEO OF ELANCO.

ELANCO ANIMAL HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

INDIANAPOLIS, IND., FEB. 19, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES.

ELANCO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

INDIANAPOLIS, FEB. 13, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED UPDATES TO ITS BOARD OF DIRECTORS. R. DAVID HOOVER AND DEBORAH KOCHEVAR WILL NOT STAND FOR RE-ELECTION AT THE CONCLUSION OF THEIR TERMS AT THE 2026 ANNUAL MEETING OF SHAREHOLDERS IN MAY.

ELANCO ANNOUNCES UPDATES TO BOARD OF DIRECTORS

INDIANAPOLIS, JAN. 22, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL ANNOUNCE ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON TUESDAY, FEBRUARY 24, 2026. ELANCO WILL ALSO CONDUCT A CONFERENCE CALL ON THAT DAY WITH THE INVESTMENT COMMUNITY AND MEDIA TO FURTHER DETAIL THE COMPANY'S PERFORMANCE.

ELANCO CONFIRMS DATE AND CONFERENCE CALL FOR FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ANNOUNCEMENT

INDIANAPOLIS, JAN. 6, 2026 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON TUESDAY, JANUARY 13, 2026.

ELANCO TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ELANCO'S SECOND DERMATOLOGY PRODUCT APPROVAL IN LESS THAN 18 MONTHS IN THE ESTIMATED $1.3 BILLION U.S. CANINE DERMATOLOGY MARKET BEFRENA HAS BEEN SHOWN TO BE EFFECTIVE FOR TREATMENT OF DOGS OF ANY AGE AGAINST CANINE ATOPIC DERMATITIS AND ALLERGIC DERMATITIS FOR 6 TO 8 WEEKS OF TREATMENT, AS NEEDED USDA APPROVAL OFBEFRENA REINFORCES ELANCO'S COMMITMENT TO GOING BEYOND TO DELIVER DIFFERENTIATED, HIGH-QUALITY PRODUCTS IN EVERY KEY THERAPEUTIC AREA, BOLSTERING ITS LEADERSHIP IN CANINE DERMATOLOGY AND MONOCLONAL ANTIBODIES (MABS) CANINE ALLERGIC ANDATOPIC DERMATITIS IS A WIDESPREAD CONCERN AMONGST VETERINARIANS, WITH DATA REVEALING THAT NEARLY 98% OF VETS SAY THEY ROUTINELY TREAT DOGS FOR ATOPIC DERMATITIS AND THAT ITCHY DOGS MAKE UP NEARLY 20% OF THEIR PATIENT POPULATIONI INDIANAPOLIS, IND., DEC. 31, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED ITS LATEST ENTRY INTO THE RAPIDLY GROWING CANINE DERMATOLOGY SPACE WITH THE U.S. DEPARTMENT OF AGRICULTURE (USDA) APPROVAL OF BEFRENA (TIRNOVETMAB), A NEW ANTI-IL31 MONOCLONAL ANTIBODY (MAB) INJECTION TARGETING CANINE ALLERGIC AND ATOPIC DERMATITIS.

ELANCO RECEIVES USDA APPROVAL FOR BEFRENA (TIRNOVETMAB), A NEW ANTI-IL31 MONOCLONAL ANTIBODY INJECTION TARGETING CANINE ALLERGIC AND ATOPIC DERMATITIS

CONDITIONAL APPROVAL MARKS ELANCO'S THIRD NEW WORLD SCREWWORM TREATMENT OPTION FOR COMPANION ANIMALS, PROVIDING MULTIPLE TREATMENT SOLUTIONS PRIOR TO FLY BEING DETECTED IN THE U.S. FDA'S CONDITIONAL APPROVAL OFCREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) IS THE FIRST FOR COMPANION ANIMALS AGAINST NEW WORLD SCREWWORM ACTION FOLLOWS PREVIOUS EMERGENCY USE AUTHORIZATIONS GRANTED BY THE FDA FORCREDELIO (LOTILANER) AND CREDELIO CAT (LOTILANER) TO TREAT NEW WORLD SCREWWORM IN DOGS AND CATS, RESPECTIVELY CREDELIO QUATTRO/CREDELIO QUATTRO-CA1 PROVIDES THE BROADEST PARASITE COVERAGE OF ITS KIND* - COVERING SEVEN TYPES OF PARASITES INCLUDING TICKS, FLEAS, HEARTWORM DISEASE, ROUNDWORMS, HOOKWORMS, TAPEWORMS, AND NOW NEW WORLD SCREWWORM** PUBLISHED LITERATURE SHOWSLOTILANER, AN ACTIVE INGREDIENT IN CREDELIO QUATTRO-CA1, HAS A REASONABLE EXPECTATION OF EFFECTIVENESS FOR THE TREATMENT OF INFESTATIONS CAUSED BY NEW WORLD SCREWWORMI INDIANAPOLIS , DEC. 18, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED IT HAS RECEIVED CONDITIONAL APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) FOR THE TREATMENT OF INFESTATIONS CAUSED BY NEW WORLD SCREWWORM LARVAE (MYIASIS) IN DOGS. THIS IS THE FIRST FDA CONDITIONAL APPROVAL FOR A COMPANION ANIMAL PRODUCT TO TREAT NEW WORLD SCREWWORM.

ELANCO'S CREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) RECEIVES FIRST FDA CONDITIONAL APPROVAL FOR TREATMENT OF NEW WORLD SCREWWORM IN DOGS

DETAILS THREE-YEAR OUTLOOK WITH ANNUAL MID-SINGLE DIGIT TOP-LINE ORGANIC CONSTANT CURRENCY GROWTH DRIVEN BY A CONSISTENT FLOW OF HIGH-IMPACT INNOVATION, HIGH-SINGLE DIGIT ADJUSTED EBITDA GROWTH AND LOW DOUBLE-DIGIT ADJUSTED EPS GROWTH, ALL STARTING IN 2026. EXPECTS FURTHER NET LEVERAGE RATIO IMPROVEMENT TO

ELANCO INVESTOR DAY DEFINES NEW ERA AS SUSTAINABLE GROWTH COMPANY

MELBOURNE, AUSTRALIA , NOV. 26, 2025 /PRNEWSWIRE/ -- NEURIZON THERAPEUTICS LIMITED (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("NEURIZON" OR "THE COMPANY"), A CLINICAL-STAGE BIOTECH COMPANY DEDICATED TO ADVANCING INNOVATIVE TREATMENTS FOR NEURODEGENERATIVE DISEASES, IS PLEASED TO ANNOUNCE THE APPOINTMENT OF MS JUSTINE CONWAY AS A BOARD OBSERVER. MS CONWAY CURRENTLY SERVES AS GLOBAL HEAD OF BUSINESS DEVELOPMENT AT ELANCO ANIMAL HEALTH ("ELANCO") (NYSE: ELAN) AND WILL PARTICIPATE IN NEURIZON'S BOARD ACTIVITIES AS ELANCO'S DESIGNATED REPRESENTATIVE.

ELANCO EXECUTIVE APPOINTED AS NEURIZON'S BOARD OBSERVER

EUA TO TREAT CATS FOR NWS ISSUED PRIOR TO FLY BEING DETECTED IN THE U.S.; ACTION PREPARES VETERINARIANS AND PET OWNERS WITH TREATMENT OPTIONS FIRST U.S. FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION (EUA) GRANTED FOR NEW WORLD SCREWWORM IN CATS, REINFORCING ELANCO'S LEADERSHIP IN FELINE INNOVATION ACTION REINFORCES THE FDA'S COMMITMENT TO ACT SWIFTLY AGAINST EMERGING ANIMAL HEALTH THREATS SCIENTIFIC STUDIES SHOWEDCREDELIO CAT MAY BE EFFECTIVE IN TREATING NEW WORLD SCREWWORM IN CATSI,II PREVENTING OPEN WOUNDS THROUGH EFFECTIVE FLEA AND TICK CONTROL IS CRITICAL IN PROTECTING PETS FROMNWS INDIANAPOLIS , NOV. 21, 2025 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED IT HAS RECEIVED EMERGENCY USE AUTHORIZATION (EUA) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CREDELIO CAT (LOTILANER) TO TREAT NEW WORLD SCREWWORM (NWS) INFESTATIONS IN CATS. THIS AUTHORIZATION REPRESENTS THE FIRST EUA GRANTED BY THE FDA FOR NEW WORLD SCREWWORM TREATMENT IN FELINES.

Elanco Animal Health Incorporated

ELAN

Price

Financial Reports

No items found.

Press Releases

Elanco Animal Health Incorporated

ELAN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELAN